Mechanistically, RAC1P29S has been shown to activate the PAK and AKT pathways and to drive a mesenchymal phenotypic switch via the SRF/MRTF transcriptional axis and promote melanoma progression and therapeutic resistance [25]. This evidence concerns the gene SRF and melanoma.